[
    [
        {
            "time": "",
            "original_text": "贝达药业：目前在针对恶性肿瘤的大分子免疫治疗方面布局了多个产品",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恶性肿瘤",
                    "大分子免疫治疗",
                    "产品布局"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：目前在针对恶性肿瘤的大分子免疫治疗方面布局了多个产品",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]